SINAY Sarl, an environmental consulting organization, provides marine and coastline environmental consulting services. It offers impact assessments, underwater acoustics, fishery science, fishing, geophysics, and geotechnical services for applications in the fields of renewable marine energies, fisheries/aquaculture, marine protected areas, oil/military, and harbors. The company was incorporated in 2007 and is based in Caen, France.
Sentryc GmbH offers software as a service software development services. Its services, include anti counterfeiting, trademark protection, copyright, product piracy, and plagiarism. The company also provides software services, such as marketplace scan, social media scan, automatic removal, documentation and reporting, and counterfeiting analysis. The company was founded in 2019 and is based in Berlin, Germany with additional offices in Barcelona, Spain and Stettin, Poland.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.
77Foods, incorporated in 2019 and headquartered in Saint-Ouen-sur-Seine, France, is focused on creating innovative food alternatives. The company is developing a 100% vegetable edible fat, aiming to provide various types of plant-based meats, with an initial focus on a bacon substitute. Through its commitment to plant-based products, 77Foods seeks to cater to the growing demand for sustainable and healthier food options.
HARDLOOP SARL sells sports products online. The company sells shoes, gloves, bottles, and more. HARDLOOP SARL was incorporated in 2014 and is based in Paris, France.
SportEasy is a comprehensive, easy-to-use, web and mobile app to manage amateur sports teams. It helps coaches organize their team's games and practices; communicate easily with their players; capture and analyze statistics. It offers players fun, social features to share their passion with their teammates (vote for player of the game, private forum, photo sharing...). SportEasy is available on the web, and as iPhone and Android apps. It is free, although premium paid plans will be available for teams and clubs starting Q1 2015. Launched in France in 2011, SportEasy is now available in French and English.
Expensya SAS is a company based in Paris, France, that specializes in developing multi-platform expense management software solutions. Founded in 2015, it provides a web application designed to streamline the management of professional expense reports. The Expensya application offers a range of features, including expense management, data export, accountant integration, archiving, email processing, mileage expense management, approval flow, cost accounting, and a statistics module. It is compatible with Android, iPhone, and Windows phone, making it accessible for users across different devices.
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
Iome Bio is a French company founded on discoveries from Sharpe and Kasper (Harvard) laboratories that explore microbiome-based mechanisms to develop new drugs in immuno-oncology. In particular, the company is working on new targets to overcome resistance to checkpoint inhibitors.
Opencell Software, founded in 2015, specializes in providing an open source monetization and billing platform designed to address the limitations of traditional billing systems and basic SaaS solutions. The company builds on a telco billing project initiated in 2007 by its CEO, David Meyer, to offer a flexible and efficient alternative for various industries, including telecommunications, cloud services, IoT, and utilities. With over 40 successful implementations globally, Opencell aims to deliver an agile solution that meets diverse billing needs while simplifying the complexities often associated with legacy systems.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
Since late 2015, they have dedicated ourselves to bring to the market an intelligent thermal technology that knows exactly how and when to keep people warm. The three Clim8 co-founders saw a tremendous need to create an ingredient brand – Clim8 – that would combine both Textile and Digital industries. While until now most of intelligent wearables were able to track user’s activities, Clim8 provides a technology that monitors, analyzes, activates and regulates accordingly to the user’s specific needs.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Saagie is leading the way in big data analytics by providing DataOps Orchestration that accelerates and operationalizes analytic projects. Their mission is to unify people, process and technology enabling organizations to deliver projects from raw data to production in weeks. Saagie delivers unmatched time-to-value, is “open by design” with isolated containers, strong network engineering as well as transparent security and governance bringing trust, privacy, audit and traceability to analytic projects. Saagie includes best-in-class integration with open source and commercial technologies to support today’s Big Data/AI and analytic use cases enabling global companies to realize value from their data intensive initiatives. Ultimately, Saagie provides a Plug and Play Orchestrator for DataOps that accelerates the distribution of Artificial Intelligence (AI) and Big Data to give companies a competitive advantage across industries.
Your Personal Robot Cameraman for INDOOR and OUTDOOR shooting.
Scipio Bioscience SAS is a biotechnology company based in Paris, France, specializing in the development and manufacture of benchtop kits designed for sample preparation in single-cell studies. Founded in 2017, the company offers innovative solutions that facilitate sequencing applications in both clinical and basic research, with a particular focus on transcriptomics. Their products enable single-cell barcoding in a test tube format, streamlining the process for researchers engaged in advanced biological studies.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
HARDLOOP SARL sells sports products online. The company sells shoes, gloves, bottles, and more. HARDLOOP SARL was incorporated in 2014 and is based in Paris, France.
HARDLOOP SARL sells sports products online. The company sells shoes, gloves, bottles, and more. HARDLOOP SARL was incorporated in 2014 and is based in Paris, France.
The company TIBOT technologies was born in May 2016: its objective, to develop solutions which facilitate the daily life of poultry farming. In 2015, Lætitia and Benoît called on the services of Cimtech, a design office in mechatronics located near Rennes (35), to assess the feasibility of a robot for poultry farming that could bring more comfort and profitability to their daily work.
FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.
JobTeaser SARL operates a recruitment platform designed for students and recent graduates, facilitating access to internships, job placements, and entry-level positions. Established in 2008 and based in Paris, France, the platform offers over 5,000 job opportunities and provides multimedia resources such as videos showcasing various companies and career paths. Additionally, JobTeaser offers career guidance, advice on job selection, and opportunities for users to engage directly with recruiters. The platform aims to enhance the job search experience for young professionals by combining practical job listings with valuable support and insights into potential career trajectories.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
Expensya SAS is a company based in Paris, France, that specializes in developing multi-platform expense management software solutions. Founded in 2015, it provides a web application designed to streamline the management of professional expense reports. The Expensya application offers a range of features, including expense management, data export, accountant integration, archiving, email processing, mileage expense management, approval flow, cost accounting, and a statistics module. It is compatible with Android, iPhone, and Windows phone, making it accessible for users across different devices.
Presto Engineering, Inc. is a provider of outsourced development operations for semiconductor and Internet of Things (IoT) device companies. Founded in 2006 and headquartered in San Jose, California, the company specializes in a wide array of services including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, wafer fabrication, and backend processing. It also offers comprehensive testing and qualification services, encompassing product debugging, reliability analysis, and failure analysis. Additionally, Presto Engineering delivers supply chain solutions and various lab services such as electrostatic discharge testing and compliance testing for high-definition multimedia interfaces. With offices in France, Thailand, and Taiwan, Presto Engineering serves a diverse client base, helping them minimize overhead, reduce risk, and accelerate time-to-market in the semiconductor industry.
Safe and simple booking of holiday rental properties
Launchmetrics is a Brand Performance Cloud that arms fashion, luxury, and beauty executives with the tools and data to create inspiring, shareworthy, and measurable experiences to attract today’s modern consumer. With over a decade of experience, the company develops software that helps companies in the fashion, luxury, and cosmetics sectors, helping them grow their businesses and streamline their processes. It is the most essential and trusted technology in the industry, yielding an unrivaled market penetration to 50% of the top 100 luxury brands worldwide in addition to fashion, beauty, and retailer giants such as Dior, Fendi, TopShop, Shiseido, NET-A-PORTER, Adidas, and more. Founded in NYC, with operating headquarters in Paris, Launchmetrics has employees in eight markets and support in five languages. The company works with over 1,000 brands as well as partners like IMG, the Council of Fashion Designers of America, the British Fashion Council, Camera Nazionale della Moda Italiana, Pitti Immagine, and Google, to accelerate their business and build lasting exposure.
Private Equity Round in 2018
MDoloris Medical Systems SAS specializes in the development and manufacturing of medical devices aimed at monitoring and alleviating patient pain. The company offers the Analgesia Nociception Index (ANI) monitors, which provide direct measurements of the autonomic nervous system's activity, along with ANI sensors and PhysioDoloris monitors. These devices are utilized in various settings, including general anesthesia, post-surgical wards, intensive care units, obstetrics, and neonatal care. The technology is particularly valuable for non-communicating patients, enabling healthcare providers to assess and manage pain effectively. Founded in 2010 and based in Loos, France, MDoloris also provides after-sales services to support its clients.
Izicap SAS, founded in 2013 and based in Nice, France, specializes in payment processing solutions for merchants and electronic banking partners. The company offers an innovative digital marketing platform that transforms payment cards into loyalty cards, enabling small merchants and acquirers to effectively engage customers. By capturing and analyzing payment card data, Izicap provides valuable insights through its dashboard and facilitates targeted digital marketing campaigns. Its services include automated loyalty programs and promotional campaigns via email and messaging, catering to a diverse clientele that includes restaurant owners, chain stores, and franchises. Izicap's solutions are designed to enhance customer loyalty and increase spending among end customers.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
Indexima is a company based in Montrouge, France, founded in 2016, that specializes in developing a data hub platform aimed at enhancing analytics for data-driven organizations. The platform facilitates immediate access to data for business analysts using popular analytics tools such as Tableau, Microsoft Power BI, Qlik, and others. By leveraging advanced technologies, including artificial intelligence and innovative indexing methods, Indexima enables rapid responses to analytical queries, regardless of the data volume involved. This capability allows companies to streamline their access to commercial, marketing, financial, and technical data, ultimately simplifying and accelerating their data analysis and science processes.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Il Etait Un Fruit is offering delicious dehydrated fruit petals. Fruits, just fruits, selected for their taste, sliced and then simply dried to preserve their nutritional value, without additives or added sugar. Fruits produced and processed in Languedoc Roussillon!
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
Scipio Bioscience SAS is a biotechnology company based in Paris, France, specializing in the development and manufacture of benchtop kits designed for sample preparation in single-cell studies. Founded in 2017, the company offers innovative solutions that facilitate sequencing applications in both clinical and basic research, with a particular focus on transcriptomics. Their products enable single-cell barcoding in a test tube format, streamlining the process for researchers engaged in advanced biological studies.
FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.
Pitchy Bros Prod SAS, founded in 2013 and based in Paris, France, offers a software as a service (SaaS) solution that simplifies the video creation process. Users can select from a variety of ready-to-use templates tailored for different scenarios, such as investor pitches or product descriptions. By uploading their own text, images, logos, and videos, users can produce a personalized video in just a few minutes. Pitchy provides flexible payment options, allowing users to either purchase the video outright or subscribe to a monthly plan, which includes hosting the video on Pitchy's platform. The company utilizes Adobe After Effects to design motion graphics templates, which are accessible through its website, ensuring a streamlined production process without manual intervention.
TargEDys SAS develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia. TargEDys SAS was incorporated in 2011 and is based in Rouen, France.
Business Table is the leader in corporate dining and corporate events, with more than 30,000 service providers, including 15,000 restaurants, 1,500 caterers and 14,000 hotels and locations across France. This innovative solution launched in 2012 allows companies, from large groups to SMEs, to streamline the management of meal costs through a simple, innovative and efficient booking, ordering and invoicing tool. To expand its service offering, Business Table has partnered with American Express, Concur, Edenred and AirPlus
Botfuel SAS is a Paris-based company founded in 2016 that provides a web-based platform for creating chatbots aimed at enhancing customer engagement for businesses. The platform utilizes artificial intelligence to develop modular and scalable chatbots, allowing companies to offer automated and personalized customer support through popular messaging channels. By facilitating interaction between businesses and their customers, Botfuel aims to improve customer service and drive sales, ultimately making customer support more profitable. The solutions provided by Botfuel enable businesses to engage effectively with their audiences while leveraging existing communication platforms.
SAS Chronotruck provides Chronotruck, an application that connects shippers and carriers in real time. It enables users to find trucks for shipments from carriers. The company was founded in 2014 and is based in Aubergenville, France. As of July 9, 2019, SAS Chronotruck operates as a subsidiary of GEFCO S.A..
Yelloan SAS, founded in 2015 and based in Paris, France, specializes in consumer credit for individuals. The company introduces a unique participatory guarantee service, whereby a group of at least five relatives of the borrower contributes to a pot amounting to 5% of the credit sought. This pot serves as collateral to support the decision-making process of banks when considering the borrower’s credit application. By leveraging the collective assurance of the borrower’s network, Yelloan aims to facilitate access to credit while mitigating risks for lenders.
Aston iTrade Finance is the global online platform dedicated to optimize trade receivables management for customers and suppliers. Their platform is dedicated to corporates, credit insurers and funders.
CryoCapCell is a biotechnology company based in Paris, France, specializing in the development and manufacturing of products for sample preparation in correlative light and electron microscopy (CLEM). Founded in 2011, the company offers a range of innovative solutions, including the CryoCapsule for conducting CLEM studies through vitrification, as well as the HPM Light µ system, which enables live cell imaging paired with vitrification techniques. Additionally, CryoCapCell provides the HPM010 kit for loading CryoCapsules into high-pressure freezers and the HPM100 kit for easy capsule fitting, along with a décapsuleur designed to facilitate freeze substitution and the subsequent processing of samples.
Skinjay SAS offers shower mixers and a collection of aromatic capsules primarily in France, Portugal, and Austria. Its capsules release essential oils aromatic power by merging it with the live warm water of the shower. The company offers its products online. Skinjay SAS was founded in 2012 and is based in Paris, France.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Every healthcare professional has the responsibility to use the latest tech innovations available to fight diseases. Artificial intelligence can sometimes exceed human expertise by unveiling unseen meaning out of huge amounts of data. At Keen Eye, they strive to make that deeper meaning available to every physician, biologist, and patient.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
Actronika builds haptic platforms enabling a seamless systems integration.
Actronika is a leader in haptics technology providing a cutting-edge vibrotactile module to integrate into client's systems.
At Actronika, they develop human-machine interface solutions using patented haptic technology.
As humans, they are born to touch in order to form relationships, to learn, and to be engaged with their environment. Faced with an ever-digitizing world, they have made it their mission to re-engage people with tangible, material experiences.
Their hardware and software make that possible.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
TargEDys SAS develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia. TargEDys SAS was incorporated in 2011 and is based in Rouen, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MilliDrop Instruments SAS specializes in the design and development of advanced cell culture machines utilizing millifluidics technology, aimed at bacteriological research and diagnostics. Incorporated in 2015 and headquartered in Paris, France, the company offers in vitro diagnostics machines capable of handling samples as small as a few picolitres. Its innovative instruments facilitate the simultaneous study of various cultures, allowing for the analysis, incubation, and manipulation of microbial populations while monitoring phenotypic diversity. MilliDrop also focuses on the development of its next-generation diagnostic instrument, the MilliDrop DIV, which aims to assist users in identifying infectious agents and determining appropriate antibiotic dosages to minimize therapeutic failures. The company’s technology supports microbiologists in conducting high-throughput phenotypic screenings for various microorganisms, including algae, fungi, bacteria, and yeasts, specifically for antimicrobial susceptibility testing.
HorseCom SAS, founded in 2015 and based in Caen, France, specializes in developing Bluetooth audio headset technology specifically designed for horses and their riders. The company aims to improve the well-being, focus, rhythm, and connection between horses and riders through innovative products and services centered around music and technology. HorseCom has created a patented wearable device that plays music tailored for both horse and rider, fostering a stronger bond and enhanced synchronization during training and competitions. This unique device is specially adapted to accommodate equine ears, promoting the horse's well-being, improving performance, and aiding in recovery.
Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
Mailjet SAS operates a cloud-based email platform tailored for marketers and developers, enabling them to efficiently manage and track both transactional and marketing emails. Founded in 2010 and headquartered in Paris, France, the company serves over 26,000 clients across 156 countries, processing nearly 1 billion emails monthly. Mailjet provides a comprehensive suite of tools, including email personalization, automation, and real-time monitoring, along with a user-friendly SaaS interface and APIs for seamless integration into various contact management systems. Its platform features advanced analytics, reporting tools, and innovative capabilities like A/B testing to enhance email campaign performance. Additionally, Mailjet offers dedicated support in multiple languages to assist clients effectively. In 2019, Mailjet became a subsidiary of Mailgun Technologies, Inc.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
Balyo SA is a French company that specializes in designing, developing, and marketing innovative material handling robots. Founded in 2005 and based in Ivry-sur-Seine, the company transforms standard forklift trucks into autonomous robots using advanced navigation technology, enabling them to operate alongside human workers without the need for additional infrastructure such as floor markings or reflectors. Balyo’s product lineup includes robotic stackers, pallet trucks, tractors, tuggers, and various types of trucks used for a range of applications, including storage, logistics, and inventory management. The company has formed strategic partnerships with leading material handling firms, including Fenwick/Linde and Yale/Hyster, to expand its reach and enhance its offerings in the market. Balyo aims to improve operational efficiency and competitiveness in warehousing and manufacturing environments, aligning with the evolving concepts of modern logistics and industrial automation.
Augure, founded in 2002 in Paris, specializes in influencer marketing software that aids brands and agencies in integrating traditional public relations with modern influencer strategies. The platform is utilized by over 1,000 communication, PR, and public affairs teams daily, enabling them to engage relevant influencers, manage campaigns, and enhance their media presence and reputation across social networks. Augure's data services team complements its software offerings by providing consulting support, helping clients interpret data to refine their influencer marketing approaches. The company operates in Europe and Latin America, serving a diverse clientele that includes major organizations such as Orange, Thales, and Château de Versailles.
Created in July 2014, Aenitis Technologies is a French start-up resulting from the work of Mauricio HOYOS and Jean-Luc AIDER, both CNRS researchers at the PMMH Laboratory (Physics and Mechanics of Heterogeneous Media at the ESPCI ParisTech, a research engineer’s school in Paris. The company focuses on medical devices’ area, where their breakthrough technologies are highly promising. Aenitis Technologies is developing innovative separation, manipulation and filtration of biological elements solutions, based on acoustophoresis technologies. The company first focuses on technological solutions that will revolutionize current practices in Public Health. Aenitis Technologies aims to become a world leader in filtering / separating solutions by acoustophoresis.
Kayentis, SAS provides data and real-time information capture and collection solutions. It offers Digital Pen Paper (DPP) solutions for the clinical trial industry. The company also provides Clin'Form that allows data written using a DPP to be recorded in an information system and shared via a Web portal. It serves life sciences, finance, and manufacturing markets.
The company was incorporated in 2004 and is headquartered in Gif sur Yvette, France.
Open Ocean is an innovative company based in Brest and Paris, which conceives since 2011 online decision-making solutions for industrial marine activities.
Their highly qualified team of oceanographers, trained in the best research oceanographic institutes of the world (UPMC, IFREMER, University of Washington) is specialized in high resolution modelling, statistical analysis and data mining.
JobTeaser SARL operates a recruitment platform designed for students and recent graduates, facilitating access to internships, job placements, and entry-level positions. Established in 2008 and based in Paris, France, the platform offers over 5,000 job opportunities and provides multimedia resources such as videos showcasing various companies and career paths. Additionally, JobTeaser offers career guidance, advice on job selection, and opportunities for users to engage directly with recruiters. The platform aims to enhance the job search experience for young professionals by combining practical job listings with valuable support and insights into potential career trajectories.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MinuteBuzz is a social media entertainment. Dealer smile MinuteBuzz is official dealer of good humor for 3 years. Each month, there are millions, 18-35, to discover the most viral stories that can be found on social networks. Native Advertising pioneer in France, MinuteBuzz brings new life to the market of online advertising
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Webinterpret S.A.S, established in 2007 and headquartered in Valbonne, France, specializes in facilitating international e-commerce for sellers and retailers. The company offers a range of solutions that enable clients to advertise and sell products on third-party online marketplaces, including Amazon and eBay, as well as through independent Webinterpret stores. With additional offices in the United Kingdom, the United States, and Poland, Webinterpret employs approximately 210 skilled e-commerce specialists who possess local market knowledge, supporting their mission to make international e-commerce accessible to all sellers.
PrestaShop SA is a prominent provider of open-source e-commerce software, enabling businesses globally to establish and manage online stores. Founded in 2007 and headquartered in Paris, France, with an additional office in Miami, the company offers a range of features, including customizable store templates and mobile responsiveness. PrestaShop is recognized as one of the most successful open-source projects in the e-commerce sector, with over 300,000 online stores utilizing its technology. The company is committed to fostering innovation through collaboration with its global community, aiming to empower users to build successful e-commerce ventures. PrestaShop has garnered accolades for its contributions to the industry, including recognition on the Inc. 5000 list of fastest-growing private companies in Europe.
Private Equity Round in 2013
Endocontrol SA is a company based in La Tronche, France, established in 2006, that specializes in developing and distributing collaborative robots, or cobots, designed to assist in laparoscopic surgery. The company offers innovative solutions such as VIKY EP, a motorized endoscope positioner, VIKY UP, a motorized uterus positioner, and JAIMY, an articulated robotized instrument for 5-mm incisions. These products aim to enhance surgical precision and ease the challenges associated with minimally invasive procedures, which, while beneficial for patients in terms of reduced scarring and quicker recovery, can be technically demanding for surgeons. Endocontrol's products are utilized by medical professionals both in France and internationally, and the company operates as a subsidiary of Canady Life Sciences, Inc.
E-Blink specializes in developing innovative solutions for the deployment of mobile network base stations. The company focuses on creating technologies that eliminate the reliance on coaxial cables and short-range fiber optics, with its flagship product, the EB1 system, leading the way. This system enhances deployment flexibility and reduces costs while facilitating better integration of equipment within the base station environment. By offering these advanced solutions, E-Blink positions itself as a leader in fronthaul technologies, catering to the evolving needs of mobile network operators.
Streamdata.io is a software developer focused on API management that specializes in real-time data streaming through its event-driven infrastructure. Founded in 2008 and headquartered in Meylan, France, the company offers three primary services: Distribute, Journey, and Discover. Distribute enables organizations to transform traditional request/response models into streams of events, while Journey provides consulting and tools to assist businesses in managing their API lifecycle. Discover helps companies catalog their digital assets to create effective APIs. Streamdata.io has collaborated with notable partners, including Xignite and Salesforce, to enhance its offerings in financial markets. The company has received several accolades, including the European Data Award at Vivatech and recognition as one of the top AI startups in France. As a subsidiary of Axway Software, Streamdata.io also contributes to industry standards like AsynchAPI and OpenAPI. The company maintains a presence both in France and the United States.
Global Bioenergies SA is a French company established in 2008, specializing in the development of a biological process to convert renewable resources into isobutene, a crucial petrochemical building block. The company is unique in Europe for its innovative approach to producing hydrocarbons through fermentation, focusing not only on isobutene but also on other gaseous olefins such as propylene and butadiene. In addition to its production efforts, Global Bioenergies offers engineering services related to gas fermentation processes and is engaged in converting industrial emissions and gaseous carbon sources into valuable chemical compounds. The company operates an industrial pilot and is constructing a demonstration plant in Germany, while preparing for its first full-scale facility through a joint venture with Cristal Union called IBN-One.
Private Equity Round in 2013
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products.
AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine).
AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products.
AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
Nexess SAS develops and sells security management solutions for nuclear and Seveso-type plants. It offers NexLink, a software platform for security and productivity; identification products, such as personal security badges, RFID tags, optical tags, high temperature RFID tags, touch based self service counters, mobile devices, rugged mobile systems, NexLink display screens, and smart cabinets; smart camera systems that offers autonomous image analysis and real time data transmission; and RFID antenna systems, which allows objects detection and surveillance in harsh environments. The company offers its products for applications, such as hazardous products traceability, smart automatic secured cabinets to manage equipments, site localization equipments and operation securing, and hazardous zone access detection. Nexess SAS was founded in 2006 and is based in Mougins, France with an additional office in Paris, France.
Recommerce Group specializes in the trade-in and remarketing of second-hand mobile phones, offering a comprehensive range of solutions for the refurbishment and resale of smartphones. The company employs advanced proprietary technologies to give new life to used devices, facilitating both buyback and resale processes. Its services encompass multi-channel trade-in solutions, including reverse logistics, data erasure, and customer support, as well as graphic design and web development for marketing initiatives. Recommerce Group also provides rental options for smartphones and tablets on flexible terms. Operating internationally, the company collaborates with prominent retailers and mobile network operators in France, Switzerland, and Spain, while maintaining a network of physical and online distribution channels. Founded in 2009 and headquartered in Paris, France, Recommerce Group also has additional offices in Grenoble, Warsaw, Madrid, and Fribourg, positioning itself as a leader in the European recommerce market.
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options.
To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.
Web Geo Services SAS, founded in 2009 and headquartered in Montpellier, France, specializes in online mapping and geolocation applications. The company provides location-based software as a service (SaaS) technology tailored for various industries, including retail, e-commerce, travel, hospitality, banking, and automotive. By leveraging Google Maps, Web Geo Services assists businesses in enhancing customer engagement and driving conversions through effective digital systems. The company has established itself as a leading partner of Google Cloud in Europe and has successfully collaborated with more than 400 large companies. Its flagship product, Woosmap, is recognized for enabling developers to integrate advanced location intelligence features into mobile applications and websites. Web Geo Services focuses on delivering innovative solutions that empower clients to optimize online customer journeys and boost revenue.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.
ProTip SA is a privately held medical device company dedicated to the development of innovative solutions for patients suffering from larynx malfunctions. Its priority focus is to develop a permanent implant for laryngectomized patients. ProTip, based in Strasbourg (Eastern France), was founded in 2004 and has since benefited from strong support from the Alsace region and Oseo, the French public agency for innovation. The company has won several prestigious awards in France. It has established partnerships with a number of academic institutions. The international expansion of the company has recently accelerated due to the ISO certification and CE mark achievement on essential product lines.
Netino specializes in monitoring social conversations and ensuring appropriate responses on a round the clock basis.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
E-Blink specializes in developing innovative solutions for the deployment of mobile network base stations. The company focuses on creating technologies that eliminate the reliance on coaxial cables and short-range fiber optics, with its flagship product, the EB1 system, leading the way. This system enhances deployment flexibility and reduces costs while facilitating better integration of equipment within the base station environment. By offering these advanced solutions, E-Blink positions itself as a leader in fronthaul technologies, catering to the evolving needs of mobile network operators.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Streamdata.io is a software developer focused on API management that specializes in real-time data streaming through its event-driven infrastructure. Founded in 2008 and headquartered in Meylan, France, the company offers three primary services: Distribute, Journey, and Discover. Distribute enables organizations to transform traditional request/response models into streams of events, while Journey provides consulting and tools to assist businesses in managing their API lifecycle. Discover helps companies catalog their digital assets to create effective APIs. Streamdata.io has collaborated with notable partners, including Xignite and Salesforce, to enhance its offerings in financial markets. The company has received several accolades, including the European Data Award at Vivatech and recognition as one of the top AI startups in France. As a subsidiary of Axway Software, Streamdata.io also contributes to industry standards like AsynchAPI and OpenAPI. The company maintains a presence both in France and the United States.
Tigerlily SAS is a social customer engagement company based in Paris, France, established in 2010. It provides a platform that enables brands, advertising agencies, and organizations to acquire, engage, and monetize customers on social media. The company offers tools such as Page Builder, which allows users to customize their Facebook page tabs to attract fans and drive traffic to their websites. Additionally, Tigerlily's platform facilitates the management of social media conversations and branding through automated processes and features that enhance web exposure, such as comments and sharing functionalities. The platform serves a diverse clientele, including marketing consultants, and aims to transform users into buyers and buyers into brand advocates through a combination of technology and expertise.
Impeto Medical is a privately owned medical device company formed in June 2005 with its corporate headquarters in Paris, France. Impeto Medical manufactures and markets devices designed for non-invasive assessment of eccrine sweat gland activity.
Talentsoft SA is a cloud-based talent management software provider, established in 2007 and headquartered in Boulogne-Billancourt, France. The company offers a comprehensive suite of solutions that include multilingual employee portals, online resumes, recruitment tools for job advertisement and employer branding, and performance management systems that facilitate employee appraisals and discussions. Additionally, Talentsoft provides talent review and development planning solutions, internal mobility management, compensation planning, and workforce planning tools. These software-as-a-service offerings are designed to enhance various aspects of talent management, such as recruitment, performance, career development, learning, and compensation. Talentsoft has achieved rapid growth, establishing a global presence with subsidiaries and affiliates across Africa, North America, Asia, and Europe. The company's strategic partnerships, particularly with major technology players, bolster its innovative capabilities and market reach.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.